Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial.
- Karakike, Eleni
- Scicluna, Brendon BP
- Roumpoutsou, Maria
- Mitrou, Ioannis
- Karampela, Niki
- Karageorgos, Athanasios
- Psaroulis, Konstantinos
- Massa, Eleni
- Pitsoulis, Achillefs
- Chaloulis, Panagiotis
- Pappa, Evanthia
- Schrijver, Irene IT
- Frantzeskaki, Niki
- Lada, Malvina
- Dauby, Nicolas
- De Bels, David
- Floros, Ioannis
- Anisoglou, Souzana
- Antoniadou, Eleni
- Patrani, Maria
- Vlachogianni, Glykeria
- Mouloudi, Eleni
- Antoniadou, Anastasia
- Grimaldi, David
- Roger, Thierry
- Wiersinga, W Joost
- Tsangaris, Iraklis
- Giamarellos-Bourboulis, Evangelos J
Publication date
January 2022
DOI Publisher
Springer Science and Business Media LLCAbstract
Clarithromycin may act as immune-regulating treatment in sepsis and acute respiratory dysfunction syndrome. However, clinical evidence remains inconclusive. We aimed to evaluate whether clarithromycin improves 28-day mortality among patients with sepsis, respiratory and multiple organ dysfunction syndrome.info:eu-repo/semantics/publishe
Add to ORKG